Coherus Oncology (CHRS) Stock
US biotech firm commercializing affordable biologic alternatives. Here's the price, business snapshot, and what's worth knowing about Coherus Oncology in October 2026.
Coherus BioSciences (CHRS) is a US-based biotechnology firm specialising in biosimilar medicines—biologic therapies developed to be highly similar to already authorised biologics. The company has pursued commercialisation of oncology-support treatments and other biosimilars while maintaining an early-stage pipeline. With a market capitalisation of about $202.24 million, Coherus faces the typical dynamics of small-cap biotechs: growth opportunity from successful product launches and partnerships, balanced against clinical, regulatory and pricing pressures. Investors should note risks including regulatory approvals, competition from other biosimilars and originator biologics, and potential cash‑flow constraints that can lead to dilution. This summary is for general educational purposes only and is not personal investment advice; consider your objectives, risk tolerance and seek independent guidance before investing. Past performance is not indicative of future results and the value of equities can fall as well as rise.
Coherus Oncology (CHRS) Stock Forecast
Analyst price target, next 12 months
$7.00
+554.2% vs today's $1.07
Price range over the last 12 months
Close to its 12-month low
Analysts covering Coherus Oncology have a consensus 12-month target of $7.00, above the current price of $1.07.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 29 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Coherus Oncology’s stock with a target price of $7, indicating strong potential growth.
Financial Health
Coherus Oncology is generating moderate revenue and cash flow, with a solid gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CHRS
China's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: 28 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Biosimilars focus
Coherus targets established biologic markets with lower‑cost alternatives; successful uptake can drive sales, though adoption varies by payer and region.
Commercial traction
Existing launches and partnerships can support revenue growth, but competition and pricing pressure may limit margins and market share.
Regulatory & funding
Approval pathways and reimbursement rules shape prospects; small‑cap balance sheet constraints may require financing, which can dilute holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
